Icatibant Viatris

Icatibant, the active ingredient in Icatibant Viatris, is a Bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients who experience sudden, potentially life‑threatening swelling. GNH USA supplies Icatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage bradykinin‑mediated angioedema conditions, providing rapid symptom relief. - Hereditary angioedema (type I/II): reduces swelling during acute attacks. - Hereditary angioedema (type III/normal C1‑INH): controls symptoms of sudden edema. - Acute bradykinin‑mediated angioedema: alleviates swelling when conventional therapy is insufficient.

Icatibant may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Laryngeal edema: swelling of the throat that may impair breathing.

When using Icatibant, consider the following safety measures. - Hypersensitivity monitoring: watch for signs of allergic reaction. - Cardiovascular caution: use carefully in patients with known heart disease. - Renal/hepatic assessment: evaluate function before initiating therapy. - Contraindication: avoid in individuals with known hypersensitivity to icatibant. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema. - Angiotensin receptor blockers: similar potential to augment bradykinin effects. - Other bradykinin B2 antagonists: additive pharmacologic activity.

Moderate Interactions (Monitor Closely): - NSAIDs: may mask early signs of an allergic reaction. - Estrogen‑containing contraceptives: can influence frequency of HAE attacks. - Concurrent biologics: monitor for overlapping immunologic effects.